Moderna Seeks $500 Million In IPO [Seeking Alpha]
Telesis Bio, Inc. (TBIO)
US:NASDAQ Investor Relations:
businesswire.com/news/home/20170630005160/en/precipio-diagnostics-transgenomic-complete-merger
Company Research
Source: Seeking Alpha
Summary Quick Take Moderna ( MRNA ) intends to raise gross proceeds of $500 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing mRNA-based technologies and treatments for a wide range of diseases. MRNA is seeking to go public at a challenging time for biopharma firms due to stock market volatility. When we learn more about the IPO, I’ll provide an update. Company & Technology Cambridge, Massachusetts-based Moderna was founded in 2010 to discover and develop mRNA-based therapeutics and vaccines across a broad array of human diseases. Management is headed by Founding CEO and Director Stéphane Bancel , who has been with the firm since 2011 was previously CEO at bioMérieux. mRNA transfers the instructions stored in DNA to make the proteins required in every living cell. Every cell in the human body leverages mRNA in the existing natural processes to produce a huge variety of proteins, including secreted,
Show less
Read more
Impact Snapshot
Event Time:
TBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBIO alerts
High impacting Telesis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TBIO
News
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipGlobeNewswire
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsGlobeNewswire
TBIO
Earnings
- 3/28/24 - Miss
TBIO
Sec Filings
- 4/18/24 - Form 8-K
- 4/9/24 - Form PRE
- 4/8/24 - Form 8-K
- TBIO's page on the SEC website